文献速递乳房整形与再造显微修复重建

减重术后自体乳房再造结局:全国性回顾性队列研究

Rebuilding After Weight Loss: A Nationwide Retrospective Cohort Study on the Outcomes of Autologous Breast Reconstruction in Post-Bariatric Patients.
PubMed 文献 · Ann Plast Surg · 2026-03-16

基于TrinetX网络133百万美国病历的回顾性队列研究,比较有减重手术史(91例)与无减重手术史(15847例)患者自体乳房再造的结局。减重手术史与积液需引流、血清肿、裂开和血肿风险升高独立相关;减重术后患者再造时总蛋白水平显著较低,与GLP-1受体激动剂使用者相比输血风险更高。建议个体化手术规划与严密围手术期监测。

要点

  • 减重手术史与积液需引流、血清肿、裂开、血肿风险升高独立相关。
  • 减重术后患者再造时BMI仍较高,总蛋白水平显著较低。
  • 与GLP-1受体激动剂使用者相比,减重术后患者输血风险更高。

核心结论

  • 有减重手术史的患者行自体乳房再造术后并发症风险升高,建议个体化手术规划和严密围手术期监测。

研究设计与样本

  • 回顾性队列研究,使用TrinetX网络查询133百万美国病历20年数据,识别行自体乳房再造的患者。
  • 共纳入91例有减重手术史和15847例无减重手术史的患者,比较术后180天内结局。
  • 采用Firth调整逻辑回归和Kaplan-Meier生存分析评估并发症风险及手术时机影响。
  • 次要分析比较有减重手术史患者与GLP-1受体激动剂暴露患者的结局。
  • 按皮瓣类型和BMI变化进行亚组分析。

主要发现

  • 有减重手术史患者BMI显著下降(平均减少8.81 kg/m²,P < 0.001),但再造时围手术期BMI更高(P = 0.04)。
  • 控制人口学因素和合并症后,减重手术史与积液需引流(OR: 2.21,P = 0.013)、血清肿(OR: 2.56,P = 0.025)、裂开(OR: 2.45,P = 0.005)和血肿(OR: 2.28,P = 0.019)风险升高独立相关。
  • 术后并发症率按再造皮瓣类型显著不同。
  • 减重术后患者再造时总蛋白水平显著较低,而白蛋白和微量营养素水平基本保留。
  • 与GLP-1受体激动剂使用者相比,减重术后患者输血风险更高。

临床怎么用

  • 对减重术后行自体乳房再造患者应加强围手术期监测,警惕积液、血清肿、裂开和血肿。
  • 术前评估应关注总蛋白水平及皮瓣类型相关风险,制定个体化手术方案。
  • 与GLP-1受体激动剂使用者相比,减重术后患者需更关注输血风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Obesity is a known risk factor for complications in autologous breast reconstruction, yet few studies evaluate outcomes after massive weight loss. As the incidence of bariatric procedures increase, more post-weight loss patients will seek reconstruction. This study compares surgical outcomes in patients with and without bariatric surgery, addressing a critical area in reconstructive planning. METHODS: A retrospective cohort study was conducted using the TrinetX network, querying a database of 133 million US medical records over 20 years. Patients undergoing autologous breast reconstruction were identified. Nutritional laboratory values were compared at the time of bariatric surgery and reconstruction, and a secondary analysis compared outcomes in patients with prior bariatric surgery versus GLP-1 receptor agonist exposure. Outcomes up to 180 days post-surgery were compared for patients with a history of bariatric surgery and those without. Primary outcomes included fluid collection requiring drainage, hematoma, seroma, dehiscence, infection, cellulitis, fat necrosis, flap failure, embolism/thrombosis, and blood transfusion within 180 days post-reconstruction. Firth's adjusted logistic regression analyses and Kaplan-Meier survival analyses were conducted to assess complication risks and the impact of surgical timing. Subgroup analyses were performed based on flap type and BMI changes. RESULTS: A total of 91 patients with a history of bariatric surgery and 15,847 without were identified. Patients with a history of bariatric surgery experienced significant BMI reduction (mean decrease 8.81 kg/m 2 , P < 0.001), yet presented with higher perioperative BMIs at reconstruction ( P = 0.04). Controlling for demographic factors and patient comorbidities, bariatric surgery was independently associated with higher risks of fluid collections requiring drainage (OR: 2.21, P = 0.013), seroma (OR: 2.56, P = 0.025), dehiscence (OR: 2.45, P = 0.005), and hematoma (OR: 2.28, P = 0.019). Postoperative complication rates varied significantly by reconstructive flap type. Total protein levels were significantly lower at the time of reconstruction in post-bariatric patients, while albumin and micronutrient levels were largely preserved. Compared with GLP-1 receptor agonist users, post-bariatric patients had a higher risk of blood transfusion. CONCLUSION: Patients with a history of bariatric surgery undergoing autologous breast reconstruction face elevated risks for postoperative complications. Individualized surgical planning and rigorous perioperative monitoring are recommended to optimize outcomes.

来源:Ann Plast Surg,查看原文。版权归原作者所有。

引用

  1. Mehdizadeh M, Taylor A, Rodriguez Espada A, et al. Rebuilding After Weight Loss: A Nationwide Retrospective Cohort Study on the Outcomes of Autologous Breast Reconstruction in Post-Bariatric Patients. Ann Plast Surg. 2026. PMID: 41838092. doi:10.1097/SAP.0000000000004698

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。